Trial Profile
An Open-label, Single-dose,Intravenous Administration Study to Compare the Pharmacokinetics and Safety of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment With Matching Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Jul 2021
Price :
$35
*
At a glance
- Drugs Remimazolam (Primary)
- Indications Anaesthesia; Sedation
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Ono Pharmaceutical
- 08 Jul 2021 Results assessing pharmacokinetic properties and safety of remimazolam in renally (EudraCT2014-004575-23) and hepatically (NCT01790607) impaired subjects, published in the British Journal of Anaesthesia.
- 05 Dec 2014 New trial record